Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'
Stifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).The analyst comments "We’re incrementally ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)